What is Cabaletta Bio, Inc.'s earnings per share (EPS)?

Cabaletta Bio, Inc. (CABA) reported diluted earnings per share of -$2.10 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cabaletta Bio, Inc. (CABA) Financials

CABA

FY2025 annual

Net Income -$167.9M -44.9% YoY

EPS (Diluted) -$2.10 YoY not available

Free Cash Flow -$132.3M -46.3% YoY

Operating Cash Flow -$131.1M -48.6% YoY

Market Cap $352.7M as of Oct 5, 2026

Price / Sales n/m no revenue reported

Price / Earnings n/m net loss, so no earnings multiple, FY2025

Price / Book 1.7x on $210.6M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 13, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CABA SEC filings page.

This page shows Cabaletta Bio, Inc. (CABA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CABA FY2025 2026-10-04

Cabaletta Bio remains a development-stage business: escalating research investment drives cash consumption, while financing increasingly reshapes its balance sheet.

From FY2023 to FY2025, research and development spending increased from $55.4M to $142.7M as operating cash flow moved from -$53.5M to -$131.1M. That parallel movement indicates the company’s expanding research program is the central cash requirement, rather than a mature operation funding itself through operating receipts.

The balance sheet is losing flexibility: between FY2024 and FY2025, total assets fell from $185.0M to $165.1M even as total liabilities rose from $32.7M to $53.0M. The current ratio also declined from 6.2x to 2.8x, so short-term balance-sheet coverage narrowed while cash use continued.

External financing is not merely supplemental; it is part of the operating model. FY2025 financing provided $100.3M against operating cash flow of -$131.1M, while shares outstanding rose from 50.7M in FY2024 to 111.3M in FY2025. The reported liquidity comparison equals 12.2 months of the latest annual operating outflow, describing the latest balance against a past spending rate rather than a forecast.

Financial Health Signals

Financial health score not available

Cabaletta Bio, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/6

Cabaletta Bio, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing

N/A

Cabaletta Bio, Inc. reported a net loss of $167.9M while operations used $131.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Cabaletta Bio, Inc. reported an operating loss of $172.2M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$51.6M

YoY-13.7%

QoQ-17.5%

Cabaletta Bio, Inc.'s EBITDA was -$51.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.7% from the same quarter a year earlier. Against the prior quarter it is down 17.5%.

Net Income

-$51.0M

YoY-13.1%

QoQ-17.2%

Cabaletta Bio, Inc. reported -$51.0M in net income in Q2 2026. This represents a decrease of 13.1% from the same quarter a year earlier. Against the prior quarter it is down 17.2%.

EPS (Diluted)

-$0.34

QoQ+12.8%

Cabaletta Bio, Inc. earned -$0.34 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 12.8%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$41.5M

YoY-35.7%

QoQ+2.5%

Cabaletta Bio, Inc. recorded an outflow of $41.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 35.7% from the same quarter a year earlier. Against the prior quarter it is up 2.5%.

Cash & Debt

$225.1M

YoY+54.6%

QoQ+93.0%

5Y CAGR+17.7%

Cabaletta Bio, Inc. held $225.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

170M

QoQ+4.0%

5Y CAGR+46.7%

Cabaletta Bio, Inc. had 170M shares outstanding in Q2 2026. Against the prior quarter it is up 4.0%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-24.2%

YoY+1.1pp

QoQ+17.9pp

Cabaletta Bio, Inc.'s ROE was -24.2% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 17.9 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$44.4M

YoY+18.0%

QoQ+18.9%

Cabaletta Bio, Inc. invested $44.4M in research and development in Q2 2026. This represents an increase of 18.0% from the same quarter a year earlier. Against the prior quarter it is up 18.9%.

Capital Expenditures

YoY-100.0%

Cabaletta Bio, Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

CABA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CABA quarterly income statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
R&D Expenses	N/A	$142.7M+46.8%	$97.2M+75.4%	$55.4M+41.0%	$39.3M+20.9%	$32.5M+52.0%	$21.4M+83.2%	$11.7M+161.3%	$4.5M
SG&A Expenses	N/A	$29.6M+5.8%	$27.9M+45.2%	$19.2M+29.6%	$14.8M+7.4%	$13.8M+10.9%	$12.5M+77.7%	$7.0M+306.3%	$1.7M
Operating Income	N/A	-$172.2M-37.6%	-$125.1M-67.6%	-$74.7M-37.9%	-$54.1M-16.9%	-$46.3M-36.9%	-$33.8M-81.1%	-$18.7M-201.7%	-$6.2M
EBITDA	N/A	-$170.6M-41.8%	-$120.3M-64.3%	-$73.2M-38.3%	-$53.0M-16.2%	-$45.6M-36.1%	-$33.5M-80.2%	-$18.6M-200.0%	-$6.2M
Interest Expense	N/A	$2.0M+167.9%	$748K	$0	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$167.9M-44.9%	-$115.9M-71.2%	-$67.7M-27.8%	-$53.0M-14.4%	-$46.3M-38.8%	-$33.3M-96.8%	-$16.9M-38.9%	-$12.2M
EPS (Basic)	N/A	-$2.10+10.3%	-$2.34-41.8%	-$1.65+8.8%	-$1.81-0.6%	-$1.80	N/A	N/A	N/A
EPS (Diluted)	—	-$2.10	-$2.34-41.8%	-$1.65+8.8%	-$1.81-0.6%	-$1.80	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
R&D Expenses	$44.4M+18.0%	$37.4M+28.7%	N/A	$39.8M+51.5%	$37.6M+60.7%	$29.0M+32.2%	N/A	$26.3M+90.7%
SG&A Expenses	$7.6M-8.2%	$6.9M-14.5%	N/A	$6.8M+0.1%	$8.3M+20.7%	$8.1M+33.6%	N/A	$6.8M+38.4%
Operating Income	-$52.0M-13.3%	-$44.3M-19.3%	N/A	-$46.6M-41.0%	-$45.9M-51.6%	-$37.1M-32.5%	N/A	-$33.0M-77.0%
EBITDA	-$51.6M-13.7%	-$44.0M-19.9%	N/A	-$46.2M-41.8%	-$45.4M-52.2%	-$36.7M-32.6%	N/A	-$32.6M-78.1%
Interest Expense	$517K-9.5%	$636K+116.3%	N/A	$584K	$571K	$294K	N/A	$0
Income Tax	$0	$0	N/A	$0	$0	$0	N/A	$0
Net Income	-$51.0M-13.1%	-$43.5M-21.1%	N/A	-$44.9M-46.5%	-$45.1M-63.5%	-$35.9M-43.5%	N/A	-$30.6M-86.2%
EPS (Basic)	-$0.34+53.4%	-$0.39+45.1%	-$0.35+46.2%	-$0.44+29.0%	-$0.73-30.4%	-$0.71-39.2%	-$0.65-38.3%	-$0.62-67.6%
EPS (Diluted)	-$0.34	-$0.39	-$0.35	-$0.44	-$0.73	-$0.71-39.2%	-$0.65-38.3%	-$0.62-67.6%
Diluted Shares (Avg)	151M	112M	N/A	N/A	62M	51M	N/A	N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.

CABA Balance Sheet

CABA quarterly balance sheet

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Total Assets	$165.1M-10.8%	$185.0M-27.0%	$253.7M+116.9%	$117.0M-7.4%	$126.3M+10.1%	$114.7M-18.9%	$141.5M+314.0%	$34.2M
Current Assets	$138.9M-16.7%	$166.7M-31.8%	$244.5M+124.6%	$108.8M-12.6%	$124.5M+9.7%	$113.5M-19.2%	$140.6M+313.5%	$34.0M
Cash & Equivalents	$83.0M-49.4%	$164.0M-15.2%	$193.2M+136.8%	$81.6M-33.2%	$122.2M+20.5%	$101.4M-25.5%	$136.2M+312.5%	$33.0M
Short-Term Investments	$50.6M	$0-100.0%	$48.0M+92.5%	$24.9M	$0-100.0%	$7.2M	$0	$0
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$53.0M+62.1%	$32.7M+87.4%	$17.5M+40.2%	$12.4M+48.5%	$8.4M+61.8%	$5.2M+64.6%	$3.1M-93.0%	$44.9M
Current Liabilities	$50.2M+85.2%	$27.1M+69.4%	$16.0M+68.6%	$9.5M+13.2%	$8.4M+61.8%	$5.2M+64.6%	$3.1M+233.7%	$943K
Non-Current Liabilities	$2.9M-48.8%	$5.6M+285.8%	$1.5M-50.7%	$3.0M	$0	$0	$0-100.0%	$43.9M
Total Equity	$112.1M-26.4%	$152.3M-35.5%	$236.2M+126.0%	$104.5M-11.4%	$118.0M+7.7%	$109.5M-20.8%	$138.3M+1393.9%	-$10.7M
Retained Earnings	-$517.0M-48.1%	-$349.1M-49.7%	-$233.2M-40.9%	-$165.6M-47.1%	-$112.6M-69.8%	-$66.3M-101.2%	-$33.0M-164.7%	-$12.5M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$256.7M+14.4%	$148.1M-10.3%	$165.1M-10.8%	$189.8M-7.2%	$224.5M+3.3%	$165.1M-31.3%	$185.0M-27.0%	$204.4M+18.0%
Current Assets	$231.0M+16.4%	$122.3M-9.1%	$138.9M-16.7%	$164.6M-11.3%	$198.4M-3.8%	$134.6M-40.8%	$166.7M-31.8%	$185.5M+11.6%
Cash & Equivalents	$225.1M+54.6%	$116.6M-11.5%	$83.0M-49.4%	$60.2M-64.7%	$145.6M-18.5%	$131.8M-24.8%	$164.0M-15.2%	$170.6M+47.7%
Short-Term Investments	$0-100.0%	$0	$50.6M	$99.7M+704.0%	$49.1M+99.4%	$0-100.0%	$0-100.0%	$12.4M-74.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$46.1M+0.3%	$44.8M+2.9%	$53.0M+62.1%	$50.3M+66.7%	$46.0M+157.1%	$43.6M+132.6%	$32.7M+87.4%	$30.2M+144.0%
Current Liabilities	$39.9M-3.9%	$41.5M+22.1%	$50.2M+85.2%	$45.7M+99.9%	$41.5M+132.1%	$34.0M+89.1%	$27.1M+69.4%	$22.9M+115.5%
Non-Current Liabilities	$6.2M+39.0%	$3.3M-65.3%	$2.9M-48.8%	$4.6M-37.5%	$4.5M	$9.6M+1154.8%	$5.6M+285.8%	$7.3M+316.9%
Total Equity	$210.6M+18.0%	$103.3M-15.0%	$112.1M-26.4%	$139.5M-20.0%	$178.5M-10.5%	$121.6M-45.2%	$152.3M-35.5%	$174.2M+8.3%
Retained Earnings	-$611.5M-42.2%	-$560.5M-45.6%	-$517.0M-48.1%	-$475.0M-50.1%	-$430.2M-50.5%	-$385.0M-49.1%	-$349.1M-49.7%	-$316.5M-49.1%

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

CABA Cash Flow Statement

CABA quarterly cash flow statement

Metric	TTM	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Operating Cash Flow	-$153.9M	-$131.1M-48.6%	-$88.2M-64.8%	-$53.5M-15.5%	-$46.4M-36.0%	-$34.1M-27.4%	-$26.8M-66.8%	-$16.0M-244.2%	-$4.7M
Depreciation & Amortization	N/A	$1.6M-65.8%	$4.8M+237.5%	$1.4M+21.1%	$1.2M+60.7%	$733K+107.1%	$354K+240.4%	$104K	$0
Stock-Based Compensation	N/A	$20.9M+7.6%	$19.5M+71.6%	$11.3M+64.5%	$6.9M+18.8%	$5.8M+32.3%	$4.4M+90.8%	$2.3M+279.5%	$606K
Capital Expenditures	$283K	$1.2M-44.4%	$2.2M+221.8%	$687K-72.0%	$2.5M+110.4%	$1.2M+83.6%	$635K-8.4%	$693K	N/A
Free Cash Flow	-$154.2M	-$132.3M-46.3%	-$90.4M-66.7%	-$54.2M-11.1%	-$48.8M-38.4%	-$35.3M-28.7%	-$27.4M-63.7%	-$16.7M	N/A
Investing Cash Flow	$50.7M	-$50.3M-206.3%	$47.3M+310.6%	-$22.5M+17.5%	-$27.2M-553.7%	$6.0M+175.2%	-$8.0M-1051.7%	-$693K	N/A
Financing Cash Flow	$182.8M	$100.3M+759.4%	$11.7M-93.8%	$187.6M+468.9%	$33.0M-32.6%	$48.9M+203862.5%	-$24K-100.0%	$119.9M+218.3%	$37.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$5.3M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$41.5M-36.4%	-$42.6M-38.2%	-$35.3M-52.9%	-$34.5M-69.8%	-$30.4M-46.4%	-$30.8M-28.4%	-$23.1M-40.6%	-$20.3M-61.2%
Depreciation & Amortization	$371K-20.7%	$337K-30.5%	$348K-25.6%	$345K-18.6%	$468K+9.9%	$485K+23.4%	$468K+39.3%	$424K+19.4%
Stock-Based Compensation	N/A	$5.3M+1.8%	N/A	N/A	N/A	$5.2M+36.1%	N/A	N/A
Capital Expenditures	$0-100.0%	$0-100.0%	$205K-45.5%	$78K-69.2%	$161K-79.1%	$785K-3.3%	$376K+103.2%	$253K+289.2%
Free Cash Flow	-$41.5M-35.7%	-$42.6M-34.7%	-$35.5M-51.3%	-$34.6M-68.1%	-$30.6M-41.9%	-$31.6M-27.4%	-$23.5M-41.3%	-$20.6M-62.4%
Investing Cash Flow	$0+100.0%	$51.0M+6591.7%	$49.8M+310.7%	-$50.1M-508.9%	-$49.2M-307.3%	-$785K+3.3%	$12.1M+967.3%	$12.2M+18941.5%
Financing Cash Flow	$150.0M+60.6%	$25.3M+4677.4%	$8.3M+90.6%	-$806K-1235.2%	$93.4M+24536.7%	-$552K-108.1%	$4.4M-95.3%	$71K-27.6%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CABA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CABA quarterly financial ratios

Metric	FY25DEF 14A	FY24DEF 14A	FY23DEF 14A	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K
Return on Equity	-149.8%-73.8pp	-76.1%-47.4pp	-28.6%+22.0pp	-50.7%-11.4pp	-39.2%-8.8pp	-30.4%-18.2pp	-12.3%	N/A
Return on Assets	-101.7%-39.1pp	-62.6%-35.9pp	-26.7%+18.6pp	-45.3%-8.7pp	-36.6%-7.6pp	-29.1%-17.1pp	-12.0%+23.7pp	-35.7%
Current Ratio	2.77-3.4x	6.15-9.1x	15.29+3.8x	11.47-3.4x	14.86-7.1x	21.92-22.7x	44.66+8.6x	36.05
Debt-to-Equity	0.47+0.3x	0.21+0.1x	0.070.0x	0.120.0x	0.070.0x	0.050.0x	0.02	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-24.2%+1.1pp	-42.1%-12.6pp	N/A	-32.2%-14.6pp	-25.3%-11.5pp	-29.6%-18.3pp	N/A	-17.6%-7.4pp
Return on Assets	-19.9%+0.2pp	-29.4%-7.6pp	N/A	-23.6%-8.7pp	-20.1%-7.4pp	-21.8%-11.3pp	N/A	-15.0%-5.5pp
Current Ratio	5.79+1.0x	2.95-1.0x	2.77-3.4x	3.60-4.5x	4.78-6.7x	3.96-8.7x	6.15-9.1x	8.11-7.5x
Debt-to-Equity	0.220.0x	0.43+0.1x	0.47+0.3x	0.36+0.2x	0.26+0.2x	0.36+0.3x	0.21+0.1x	0.17+0.1x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Cabaletta Bio, Inc. CABA	FY2025	N/A	-$167.9M	N/A	$352.7M	—
Kyverna Therapeutics, Inc. KYTX	FY2025	N/A	-$161.3M	N/A	$384.7M	—
Aardvark Therapeutics, Inc. AARD	FY2025	$5.1M	-$57.6M	N/A	$109.2M	55/100
Caribou Biosciences, Inc. CRBU	FY2025	$11.2M	-$148.1M	N/A	$130.8M	52/100
Ventyx Biosciences, Inc. VTYX	FY2024	N/A	-$135.1M	N/A	$1.0B	—
Climb Bio, Inc. CLYM	FY2025	N/A	-$59.9M	N/A	$628.4M	—

Where Cabaletta Bio, Inc. Ranks

Frequently Asked Questions

Is Cabaletta Bio, Inc. profitable?

No, Cabaletta Bio, Inc. (CABA) reported a net income of -$167.9M in fiscal year 2025.

What is Cabaletta Bio, Inc.'s EBITDA?

Cabaletta Bio, Inc. (CABA) had EBITDA of -$170.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Cabaletta Bio, Inc.'s return on equity (ROE)?

Cabaletta Bio, Inc. (CABA) has a return on equity of -149.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cabaletta Bio, Inc.'s free cash flow?

Cabaletta Bio, Inc. (CABA) recorded an outflow of $132.3M in free cash flow during fiscal year 2025. This represents a -46.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cabaletta Bio, Inc.'s operating cash flow?

Cabaletta Bio, Inc. (CABA) recorded an outflow of $131.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Cabaletta Bio, Inc.'s total assets?

Cabaletta Bio, Inc. (CABA) had $165.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cabaletta Bio, Inc.'s capital expenditures?

Cabaletta Bio, Inc. (CABA) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Cabaletta Bio, Inc. spend on research and development?

Cabaletta Bio, Inc. (CABA) invested $142.7M in research and development during fiscal year 2025.

How many shares does Cabaletta Bio, Inc. have outstanding?

Cabaletta Bio, Inc. (CABA) had 111M shares outstanding as of fiscal year 2025.

What is Cabaletta Bio, Inc.'s current ratio?

Cabaletta Bio, Inc. (CABA) had a current ratio of 2.77 as of fiscal year 2025, which is generally considered healthy.

What is Cabaletta Bio, Inc.'s debt-to-equity ratio?

Cabaletta Bio, Inc. (CABA) had a debt-to-equity ratio of 0.47 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cabaletta Bio, Inc.'s return on assets (ROA)?

Cabaletta Bio, Inc. (CABA) had a return on assets of -101.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cabaletta Bio, Inc.'s P/E ratio?

Cabaletta Bio, Inc. (CABA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $352.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Cabaletta Bio, Inc.'s price-to-sales ratio?

Cabaletta Bio, Inc. (CABA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $352.7M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Cabaletta Bio, Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Cabaletta Bio, Inc. (CABA) held $133.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $131.1M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Cabaletta Bio, Inc.'s Piotroski F-Score?

Cabaletta Bio, Inc. (CABA) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cabaletta Bio, Inc.'s earnings high quality?

Cabaletta Bio, Inc. (CABA) reported a net loss of $167.9M while operations used $131.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Cabaletta Bio, Inc. cover its interest payments?

Cabaletta Bio, Inc. (CABA) reported an operating loss of $172.2M against $2.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.